Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth J Baum

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
American Journal of Preventive Cardiology|December 11, 2025
Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted <i>APOC3</i> antisense oligonucleotideArchna Bajaj, Elif A Oral, Alan Brown, et al.
American Journal of Preventive Cardiology|July 30, 2021
Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United StatesSeth J Baum, Pallavi B Rane, Sasikiran Nunna, et al.
American Journal of Preventive Cardiology|November 8, 2021
Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statinsHarold E Bays, Seth J Baum, Eliot A Brinton, et al.
American Journal of Preventive Cardiology|December 25, 2025
Cholesterol management in US adults with ASCVD in the Family Heart Database® during 2022-23: Current state of care and opportunities for improvementDiane E MacDougall, Keith Ferdinand, Seth J Baum, et al.
American Journal of Preventive Cardiology|November 25, 2022
Defining preventive cardiology: A clinical practice statement from the American Society for Preventive CardiologyCharles A German, Seth J Baum, Keith C Ferdinand, et al.
Circulation|April 28, 2017
Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular DiseaseJoshua W Knowles, William B Howard, Lala Karayan, et al.
Pancreas|December 4, 2025
Episodic and Long-Term Costs of Acute Pancreatitis Requiring Hospitalization among Adults in US Clinical PracticeAsia Sikora Kessler, Daniel E Soffer, Lisa Abramovitz, et al.
Journal of Clinical Lipidology|November 25, 2019
Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL studySeth J Baum, Tiziana Sampietro, Dev Datta, et al.
American Journal of Preventive Cardiology|December 17, 2025
Temporal patterns of triglyceride testing and test results among adults with severe or extreme hypertriglyceridemia in US clinical practiceAsia Sikora Kessler, Seth J Baum, Emily Kutrieb, et al.
Circulation. Cardiovascular Quality and Outcomes|July 24, 2019
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular OutcomesKelly D Myers, Niloofar Farboodi, Mkaya Mwamburi, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
American Journal of Preventive Cardiology|December 11, 2025
Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted <i>APOC3</i> antisense oligonucleotideArchna Bajaj, Elif A Oral, Alan Brown, et al.
American Journal of Preventive Cardiology|July 30, 2021
Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United StatesSeth J Baum, Pallavi B Rane, Sasikiran Nunna, et al.
American Journal of Preventive Cardiology|November 8, 2021
Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statinsHarold E Bays, Seth J Baum, Eliot A Brinton, et al.
American Journal of Preventive Cardiology|December 25, 2025
Cholesterol management in US adults with ASCVD in the Family Heart Database® during 2022-23: Current state of care and opportunities for improvementDiane E MacDougall, Keith Ferdinand, Seth J Baum, et al.
American Journal of Preventive Cardiology|November 25, 2022
Defining preventive cardiology: A clinical practice statement from the American Society for Preventive CardiologyCharles A German, Seth J Baum, Keith C Ferdinand, et al.
Circulation|April 28, 2017
Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular DiseaseJoshua W Knowles, William B Howard, Lala Karayan, et al.
Pancreas|December 4, 2025
Episodic and Long-Term Costs of Acute Pancreatitis Requiring Hospitalization among Adults in US Clinical PracticeAsia Sikora Kessler, Daniel E Soffer, Lisa Abramovitz, et al.
Journal of Clinical Lipidology|November 25, 2019
Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL studySeth J Baum, Tiziana Sampietro, Dev Datta, et al.
American Journal of Preventive Cardiology|December 17, 2025
Temporal patterns of triglyceride testing and test results among adults with severe or extreme hypertriglyceridemia in US clinical practiceAsia Sikora Kessler, Seth J Baum, Emily Kutrieb, et al.
Circulation. Cardiovascular Quality and Outcomes|July 24, 2019
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular OutcomesKelly D Myers, Niloofar Farboodi, Mkaya Mwamburi, et al.
Pageof 9